A Phase 1, Single Center, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL346 in Healthy Caucasian and Japanese Adult Subjects

Trial Profile

A Phase 1, Single Center, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL346 in Healthy Caucasian and Japanese Adult Subjects

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs CSL 346 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; First in man
  • Sponsors CSL
  • Most Recent Events

    • 15 Nov 2017 Status changed from recruiting to not yet recruiting.
    • 10 Feb 2017 According to a CSL media release, this trial is expected to initiate in 2017.
    • 07 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top